Review



v920 013 prepare us  (Eppendorf AG)


Bioz Verified Symbol Eppendorf AG is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Eppendorf AG v920 013 prepare us
    Summary of clinical trial programs.
    V920 013 Prepare Us, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 96/100, based on 617 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v920+013+prepare+us/Label/pmc07996233-22-0-44
    Average 96 stars, based on 617 article reviews
    v920 013 prepare us - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Development of Pandemic Vaccines: ERVEBO Case Study"

    Article Title: Development of Pandemic Vaccines: ERVEBO Case Study

    Journal: Vaccines

    doi: 10.3390/vaccines9030190

    Summary of clinical trial programs.
    Figure Legend Snippet: Summary of clinical trial programs.

    Techniques Used: Injection, Immunopeptidomics

    Related Articles

    Injection:

    Article Title: Development of Pandemic Vaccines: ERVEBO Case Study
    Article Snippet: V920-012 Lot Consistency US, Canada, Spain NCT02503202 , Randomized placebo-controlled, safety and lot consistency immunogenicity study [ ] , [MSD, a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA] BARDA; Dalhousie University , 1061 , 2 × 10 7 ( n = 797) 1 × 10 8 ( n = 264) Placebo ( n = 133) , Yes , 19.1 , Day 1–42 ¥ , Day 1 to 42 , Day 1 to Month 24 , Not collected , As needed for arthralgia, arthritis, rash or vesicles— follow-up only.Day 1–42 ¥ , Day 1 to 42 , Day 1 to Month 24 , Not collected , As needed for arthralgia, arthritis, rash or vesicles— follow-up only. ... V920-013 PREPARE US, Canada NCT02788227 , Randomized open-label, booster or no booster at 18 months in individuals at potential occupational risk , [NIH/NIAID] BARDA, University of Texas, Galveston, TX, Emory University, PHAC, Winnipeg; CIRN, University of Nebraska Medical Center, Boston Medical Center/Boston University, Universitätsklinikum Hamburg-Eppendorf , Planned enrollment N up to 1000 , 2 × 10 7 , Yes , N/A , Day 1–14, Month 1, Month 18 (booster), Month 19 (post-booster) , Day 1–42 , Day 1 to Year 3 , Not collected , Not collected.. V920-015 ACHIV Canada, Burkina Faso, Senegal NCT03031912 , Randomized double-blind, placebo- controlled, one or two doses of rVSVΔG-ZEBOV-GP , [Dalhousie University] BARDA, CIRN , Planned enrollment ~250 , 2 × 10 7 pfu/mL (n~200) Placebo (n~50) , Yes , N/A , Day 1, 3, 7, 14, 28, 42 , Day 1, 3, 7, 14, 28, 42 , Day 0–365 , Day 3, 7, 14, 28, 42 , Only as clinically needed.V920-015 ACHIV Canada, Burkina Faso, Senegal NCT03031912 , Randomized double-blind, placebo- controlled, one or two doses of rVSVΔG-ZEBOV-GP , [Dalhousie University] BARDA, CIRN , Planned enrollment ~250 ,..

    Immunopeptidomics:

    Article Title: Development of Pandemic Vaccines: ERVEBO Case Study
    Article Snippet: V920-012 Lot Consistency US, Canada, Spain NCT02503202 , Randomized placebo-controlled, safety and lot consistency immunogenicity study [ ] , [MSD, a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA] BARDA; Dalhousie University , 1061 , 2 × 10 7 ( n = 797) 1 × 10 8 ( n = 264) Placebo ( n = 133) , Yes , 19.1 , Day 1–42 ¥ , Day 1 to 42 , Day 1 to Month 24 , Not collected , As needed for arthralgia, arthritis, rash or vesicles— follow-up only.Day 1–42 ¥ , Day 1 to 42 , Day 1 to Month 24 , Not collected , As needed for arthralgia, arthritis, rash or vesicles— follow-up only. ... V920-013 PREPARE US, Canada NCT02788227 , Randomized open-label, booster or no booster at 18 months in individuals at potential occupational risk , [NIH/NIAID] BARDA, University of Texas, Galveston, TX, Emory University, PHAC, Winnipeg; CIRN, University of Nebraska Medical Center, Boston Medical Center/Boston University, Universitätsklinikum Hamburg-Eppendorf , Planned enrollment N up to 1000 , 2 × 10 7 , Yes , N/A , Day 1–14, Month 1, Month 18 (booster), Month 19 (post-booster) , Day 1–42 , Day 1 to Year 3 , Not collected , Not collected.. V920-015 ACHIV Canada, Burkina Faso, Senegal NCT03031912 , Randomized double-blind, placebo- controlled, one or two doses of rVSVΔG-ZEBOV-GP , [Dalhousie University] BARDA, CIRN , Planned enrollment ~250 , 2 × 10 7 pfu/mL (n~200) Placebo (n~50) , Yes , N/A , Day 1, 3, 7, 14, 28, 42 , Day 1, 3, 7, 14, 28, 42 , Day 0–365 , Day 3, 7, 14, 28, 42 , Only as clinically needed.V920-015 ACHIV Canada, Burkina Faso, Senegal NCT03031912 , Randomized double-blind, placebo- controlled, one or two doses of rVSVΔG-ZEBOV-GP , [Dalhousie University] BARDA, CIRN , Planned enrollment ~250 ,..



    Similar Products

    v920 013 prepare us  (Eppendorf AG)
    96
    Eppendorf AG v920 013 prepare us
    Summary of clinical trial programs.
    V920 013 Prepare Us, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v920+013+prepare+us/Label/pmc07996233-22-0-44
    Average 96 stars, based on 1 article reviews
    v920 013 prepare us - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of clinical trial programs.

    Journal: Vaccines

    Article Title: Development of Pandemic Vaccines: ERVEBO Case Study

    doi: 10.3390/vaccines9030190

    Figure Lengend Snippet: Summary of clinical trial programs.

    Article Snippet: V920-013 PREPARE US, Canada NCT02788227 , Randomized open-label, booster or no booster at 18 months in individuals at potential occupational risk , [NIH/NIAID] BARDA, University of Texas, Galveston, TX, Emory University, PHAC, Winnipeg; CIRN, University of Nebraska Medical Center, Boston Medical Center/Boston University, Universitätsklinikum Hamburg-Eppendorf , Planned enrollment N up to 1000 , 2 × 10 7 , Yes , N/A , Day 1–14, Month 1, Month 18 (booster), Month 19 (post-booster) , Day 1–42 , Day 1 to Year 3 , Not collected , Not collected.

    Techniques: Injection, Immunopeptidomics